Randy D. Gascoyne
BC Cancer Agency
603 Papers
4.3K Citations
Randy D. Gascoyne is an academic researcher from BC Cancer Agency. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Lymphoma. The author has an hindex of 120, co-authored 603 publications. Previous affiliations of Randy D. Gascoyne include Queen Mary University of London & Vancouver General Hospital.
Chat about Author
Papers
Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing
Jeremy Parker,Yaoqing Shen,Erin Pleasance,Yvonne Y. Li,Jacqueline E. Schein,Yongjun Zhao,Richard A. Moore,Joanna Wegrzyn-Woltosz,Kerry J. Savage,Andrew P. Weng,Randy D. Gascoyne,Steven J.M. Jones,Marco A. Marra,Janessa Laskin,Aly Karsan +14 more
- 01 Mar 2016
TL;DR: In this patient, the molecular variants that the authors believe to be most relevant to the disease presentation most strongly resemble a diffuse large B-cell lymphoma (DLBCL), whereas the gene expression data are most consistent with a low-grade chronic lymphocytic leukemia (CLL).
High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma
Pei-Yu Kuo,Violetta V. Leshchenko,Tobias A. Gellen,Netha Ulahannan,Paul Zumbo,Christopher E. Mason,Wyndham H. Wilson,Adrian Wiestner,K. Stephen Suh,Andre Goy,David T. Yang,Brad S. Kahl,Randy D. Gascoyne,Ari Melnick,Samir Parekh +14 more
TL;DR: It is suggested that the prognostic impact of SOX11 is heterogenous, and a subset of patients with highSOX11 expression may have improved survival, and high-resolution whole-genome chromatin immunoprecipitation sequencing (ChIP-Seq) identifies more than 800 novel SoX11 direct binding targets.
1
Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.
Khaled M. Ramadan,Joseph M. Connors,Abdulwahab J. Al-Tourah,Randy D. Gascoyne,Kevin W. Song,Michael J. Barnett,Stephen H. Nantel,Thomas J. Nevill,John D. Shepherd,Heather J. Sutherland,Julye C. Lavoie,Donna L. Forrest,Donna E. Hogge,Nicholas Voss,Ryan R. Brinkman,Clayton A. Smith,Cynthia L. Toze +16 more
TL;DR: Prior treatment with ritux in patients with relapsed composite L/I-NHL undergoing SCT was associated with reduced risk of REL and improved survival without associated increase in toxicity.
1
Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT.
Khaled M. Ramadan,Kevin W. Song,Joseph M. Connors,Abdul Al-Tourah,Randy D. Gascoyne,Michael J. Barnett,Stephen H. Nantel,Thomas J. Nevill,John D. Shepherd,Heather J. Sutherland,Julye C. Lavoie,Donna L. Forrest,Donna E. Hogge,Nicholas Voss,Ryan R. Brinkman,Yasser Abou Mourad,Maryse M. Power,Sujaatha Narayanan,Clayton A. Smith,Cynthia L. Toze +19 more
TL;DR: There were no significant differences between baseline characteristics for the two groups including: median age at diagnosis, stage, B-symptoms, IPI at diagnosis), number of prior therapies, CMV status of donor and recipient, donor type, level of HLA matching and conditioning regimen.
1
The Use Of GDP (Gemcitabine, Dexamethasone and Cisplatin) in The Primary Therapy Of Peripheral T-Cell Lymphomas
Jean-Michel Lavoie,Joseph M. Connors,Diego Villa,Richard Klasa,Tamara Shenkier,Randy D. Gascoyne,Alina S. Gerrie,Laurie H. Sehn,Kerry J. Savage +8 more
TL;DR: Outcomes in high IPI patients compare favourably with historical results using CHOP chemotherapy and suggest that it may be able to overcome disease resistance in this poor risk group, providing rationale to explore it in further in future clinical trials of PTCLs.
1